These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Dingemanse J; Jorga K; Zürcher G; Schmitt M; Sedek G; Da Prada M; Van Brummelen P Br J Clin Pharmacol; 1995 Sep; 40(3):253-62. PubMed ID: 8527287 [TBL] [Abstract][Full Text] [Related]
49. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat. Männistö PT; Tuomainen P; Tuominen RK Br J Pharmacol; 1992 Mar; 105(3):569-74. PubMed ID: 1628144 [TBL] [Abstract][Full Text] [Related]
50. Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat. Bonifácio MJ; Torrão L; Loureiro AI; Palma PN; Wright LC; Soares-da-Silva P Br J Pharmacol; 2015 Apr; 172(7):1739-52. PubMed ID: 25409768 [TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. Heikkinen H; Saraheimo M; Antila S; Ottoila P; Pentikäinen PJ Eur J Clin Pharmacol; 2001; 56(11):821-6. PubMed ID: 11294372 [TBL] [Abstract][Full Text] [Related]
52. Effect of intracerebral 6-nitronoradrenaline, an endogenous catechol-O-methyltransferase (COMT) inhibitor, on striatal dopamine metabolism in anaesthetised rats. Huotari M; Passlin M; Nordberg HL; Forsberg M; Kotisaari S; Tuomisto L; Shintani F; Tanaka KF; Reenilä I; Laitinen K; Männistö PT J Neurosci Methods; 2001 Aug; 109(1):47-52. PubMed ID: 11489299 [TBL] [Abstract][Full Text] [Related]
53. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial. Corvol JC; Bonnet C; Charbonnier-Beaupel F; Bonnet AM; Fiévet MH; Bellanger A; Roze E; Meliksetyan G; Ben Djebara M; Hartmann A; Lacomblez L; Vrignaud C; Zahr N; Agid Y; Costentin J; Hulot JS; Vidailhet M Ann Neurol; 2011 Jan; 69(1):111-8. PubMed ID: 21280081 [TBL] [Abstract][Full Text] [Related]
54. Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone. Vieira-Coelho MA; Soares-da-Silva P Br J Pharmacol; 1996 Feb; 117(3):516-520. PubMed ID: 8821542 [TBL] [Abstract][Full Text] [Related]
55. Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease. Lees AJ CNS Neurosci Ther; 2008; 14(1):83-93. PubMed ID: 18482101 [TBL] [Abstract][Full Text] [Related]
56. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease. Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066 [TBL] [Abstract][Full Text] [Related]
57. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. Dingemanse J; Jorga K; Zürcher G; Fotteler B; Sedek G; Nielsen T; van Brummelen P Eur J Clin Pharmacol; 1996; 50(1-2):47-55. PubMed ID: 8739811 [TBL] [Abstract][Full Text] [Related]